Table 2.

The results of subgroup analyses on the survival efficacy of celecoxib combined with palliative therapy.

	HR	95%CI	p-Value	Heterogeneity (I2, p-Value)
Overall survival
Concomitant therapy methods
Chemotherapy	1.08	0.96–1.21	0.23	0.00%, 0.79
Chemoradiotherapy	0.99	0.69–1.43	0.96	0.00%, 0.96
Therapy stages
First-line	1.03	0.93–1.15	0.59	0.00%, 0.91
≥First-line	0.93	0.64–1.34	0.68	0.00%, 0.86
COX-2 status
High COX-2 status	0.94	0.67–1.31	0.70	62.60%,0.05
Low COX-2 status	1.13	0.78–1.64	0.53	51.50%, 0.13
PGEM status
High PGEM status	0.79	0.47–1.34	0.39	0.00%, 0.49
Low PGEM status	1.27	0.89–1.81	0.19	0.00%, 0.90
EGFR status
EGFR wild-type	1.03	0.62–1.70	0.92	0.00%, 0.99
Use of NSAIDs
No use of NSAIDs	0.98	0.81–1.18	0.80	0.00%, 0.61
Use of NSAIDs	0.66	0.23–1.91	0.44	64.30%, 0.09
Performance Status (PS, WHO)
PS: 0	0.88	0.66–1.19	0.41	0.00%, 0.89
PS: ≥1	1.02	0.83–1.25	0.86	0.00%, 0.40
Sample size
<200	1.12	0.92–1.36	0.27	0.00%, 0.71
≥200	1.02	0.91–1.15	0.69	0.00%, 0.87
Progression-free survival
Concomitant therapy strategies
Chemotherapy	1.02	0.91–1.15	0.75	0.00%, 0.47
Therapy stages
First-line	1.01	0.89–1.15	0.83	0.00%, 0.44
≥First-line	0.85	0.62–1.18	0.34	0.00%, 0.74
COX -2 status
High COX-2 status	1.03	0.82–1.30	0.79	0.00%, 0.86
PGEM status
High PGEM status	0.71	0.48–1.07	0.10	0.00%, 0.74
Low PGEM status	1.05	0.78–1.42	0.73	0.00%, 0.33
EGFR status
EGFR wild-type	0.57	0.35–0.94	0.03	0.00%, 0.72
Sample size
<200	0.99	0.81–1.20	0.90	0.00%, 0.63
≥200	1.03	0.90–1.18	0.65	9.70%, 0.35

HR: hazard ratio; CI: confidence interval; I²: showed the degree of heterogeneity; COX-2: cyclooxygenase-2; PGEM: the urinary metabolite of prostaglandin E₂; EGFR: epidermal growth factor receptor; NSAIDs: nonsteroidal anti-inflammatory drugs; PS: performance status; WHO: World Health Organization.3.4. Celecoxib and Progression-Free Survival (PFS) in Palliative Therapy.